ValiRx PLC Director/PDMR Shareholding (5433V)
August 07 2020 - 9:20AM
UK Regulatory
TIDMVAL
RNS Number : 5433V
ValiRx PLC
07 August 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Director Dealing
London, UK 7 August 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company announces the following dealing in the
ordinary shares of the Company made by a Director.
On 7 August 2020, the Company was informed that Dr Kevin Cox,
Non-executive Chairman of the Company, acquired 117,000 ValiRx
ordinary shares at an average price of 8.2 pence per share on 7
August 2020, representing approximately 0.22% of the Company's
issued ordinary share capital. Following this acquisition, Dr Cox
now holds an interest in 250,333 ValiRx ordinary shares,
representing approximately 0.46% of the Company's issued ordinary
share capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073
2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP(Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ --------------------------------------------------------------------------------
a. Name Dr Kevin Cox
-------------------------------------
2 Reason for notification
----------------------------------------- -------------------------------------
a. Position/Status Non-executive Chairman
----------------------------------------- -------------------------------------
b. Initial notification/ Initial
Amendment
----------------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a. Name ValiRx PLC
-----------------------------------------
b. LEI 213800VQKB9SJCQDET40
----------------------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ --------------------------------------------------------------------------------
a. Description of Ordinary Shares
the financial
instrument, type
of instrument ISIN: GB00BLH13C52
Identification
Code
----------------------------------------- -------------------------------------
b. Nature of the On market Purchase
transaction
----------------------------------------- -------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------- ----------------
8.2 pence 117,000
----------------------------------------------------------------- --------------
d. Aggregated information
- Aggregated Volume N/A
- Price
----------------------------------------- -------------------------------------
e. Date of the transaction 07/08/2020
----------------------------------------- -------------------------------------
f. Place of the transaction London, UK
----------------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBXGDIIBGDGGR
(END) Dow Jones Newswires
August 07, 2020 09:20 ET (13:20 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024